Moderna Study Finds Lower COVID-19 Risks Versus Comirnaty

An observational study of 294,499 U.S. veterans aged 65 and older associated mNEXSPIKE with 35.9% lower risk of medically attended COVID-19 and 47.0% lower risk of COVID-19-associated hospitalization than Comirnaty. The findings do not establish causality.